Occurrence and Management of Immunotherapy-Associated Adverse Events in Patients with Gynecological Cancers
Background: Immune checkpoint inhibitors (ICIs) have emerged as an essential therapeutic approach in treating many solid tumors. ICIs enhance the body’s anti-tumor T-cell activity, resulting in a novel spectrum of immunotherapy-related side effects. This novel spectrum of adverse events differs sign...
Main Authors: | Ina Shehaj, Maria Schröder, Valerie Catherine Linz, Slavomir Krajnak, Katrin Almstedt, Kathrin Stewen, Roxana Schwab, Annette Hasenburg, Marcus Schmidt, Anne-Sophie Heimes |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2024-03-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/16/7/1371 |
Similar Items
-
Prognostic Impact of LAG-3 mRNA Expression in Early Breast Cancer
by: Anne-Sophie Heimes, et al.
Published: (2022-10-01) -
Effects of intermittent fasting on quality of life tolerance of chemotherapy in patients with gynecological cancers: study protocol of a randomized-controlled multi-center trial
by: Mona Wanda Schmidt, et al.
Published: (2023-07-01) -
Chinese expert consensus on immunotherapy for gynecological malignant tumors (2023 edition)
by: Society of Onco-Endocrinology of Chinese Anti-Cancer Association
Published: (2023-10-01) -
Prognostic Impact of CD38- and IgκC-Positive Tumor-Infiltrating Plasma Cells in Triple-Negative Breast Cancer
by: Anne-Sophie Heimes, et al.
Published: (2023-10-01) -
Current Status and Prospects of Immunotherapy for Gynecologic Melanoma
by: Mayuka Anko, et al.
Published: (2021-05-01)